Wall Street Zen Upgrades Tyra Biosciences (NASDAQ:TYRA) to “Hold”

Tyra Biosciences (NASDAQ:TYRA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. Oppenheimer reissued an “outperform” rating and issued a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday, August 22nd. Raymond James Financial began coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Tyra Biosciences Trading Down 2.8%

Tyra Biosciences stock opened at $21.50 on Friday. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $22.83. The stock has a market cap of $1.15 billion, a P/E ratio of -11.50 and a beta of 1.08. The stock has a 50 day moving average of $16.31 and a 200-day moving average of $12.77.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). As a group, equities analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Robert J. More sold 246,871 shares of the stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the sale, the director directly owned 3,833,425 shares in the company, valued at approximately $77,626,856.25. This represents a 6.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

Several large investors have recently added to or reduced their stakes in the stock. HighVista Strategies LLC boosted its holdings in shares of Tyra Biosciences by 4.3% during the second quarter. HighVista Strategies LLC now owns 24,962 shares of the company’s stock valued at $239,000 after acquiring an additional 1,021 shares during the period. American Century Companies Inc. lifted its position in Tyra Biosciences by 5.8% in the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock valued at $218,000 after purchasing an additional 1,289 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares during the period. US Bancorp DE grew its position in Tyra Biosciences by 50.5% in the 1st quarter. US Bancorp DE now owns 5,435 shares of the company’s stock worth $51,000 after purchasing an additional 1,823 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after purchasing an additional 1,841 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.